Biopharmaceutical

Woman standing on scales
#Biopharmaceutical #Clinical trial #GLP-1 #Weight loss

Verdiva Bio completes enrolment for oral GLP-1 trial 

Biopharmaceutical company Verdiva Bio has completed its participant enrolment for the Phase IIb study of its once-weekly oral GLP-1.  VRB-101 is a once-weekly oral, cAMP-biased, GLP-1 peptide analogue candidate for body weight reduction in people with overweight or obesity.  The Phase IIb EVOLVE-2 trial is randomised, double-blind… Read More

#News

Peanuts
#Allergy #Biopharmaceutical

Prota awarded for research on peanut oral immunotherapy

Biopharmaceutical company Prota Therapeutics has announced its research, in partnership with Murdoch Children’s Research Institute (MCRI), has been awarded a prize at the European Academy of Allergy and Clinical Immunology (EAACI) for outstanding oral abstract presentation.  The presentation reported three-year post-treatment findings from the Phase IIb PPOIT-003… Read More

#News

Seattle
#Biopharmaceutical #Biotech hubs #Charles River #Laboratory #United States

Charles River opens facilities within two US life science hubs

Charles River Laboratories has revealed plans to open Charles River Accelerator and Development Lab (CRADL) locations in Seattle and Philadelphia, expanding the company’s contract vivarium space for the biopharmaceutical industry. CRADL Seattle is opening this September as Charles River’s most recent investment in Seattle, providing flexible… Read More

#News

DNA biopharma image
#Biopharmaceutical #Biotechnology #Drug discovery #Sustainability

Future trends: biopharma to outpace small molecule drug development  

Gary Connors, Partner at business consulting company Oliver Wight EAME looks at some of the most important factors that will affect the pharmaceutical industry going forward.   We advise all our clients to make assumptions and think about scenarios that could affect their business at least five years in advance. Read More

#Exclusive Content

Japanese flag
#Biopharmaceutical #Collaboration #Drug discovery #Healthcare #Investment #Life sciences #Market reporting #Start-ups

A review of Japan’s drug discovery landscape  

DDW Multimedia Editor Megan Thomas takes a broad look at the drug discovery and development landscape in Japan and highlights how it is bolstered by government policies, investment, collaboration, start-up ecosystems and academic research.   Japan continues to be one of the largest pharmaceutical markets in the world, despite what the… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Market Reports #Trends & Analysis

MicroRNA
#Biopharmaceutical #Drug development #Pharmaceuticals #Therapeutics

Regulus appoints VP of chemistry and pharmaceutical development 

Regulus Therapeutics, a biopharmaceutical company focused on the discovery and development of medicines targeting microRNAs, has appointed Mohammad Ahmadian as Vice President of Chemistry and Pharmaceutical Development.   The role  In his role, Dr. Ahmadian will assist in managing research and development of the company’s drug… Read More

#News

#Biomedicine #Biopharmaceutical #Drug discovery #Mass spectrometry / NMR

Partnership to accelerate clone selection and process development 

Waters Corporation and Sartorius have partnered to provide bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.   The partnership will implement the BioAccord LC-MS System from Waters as a new bioprocess analyser with data connectivity to Sartorius’… Read More

#News

#AI / data analytics / healthtech / informatics #Biopharmaceutical #Drug discovery #Machine learning

The value of scientific intelligence in drug discovery

Leif Pedersen, President, Software, and David Lowis, Executive Director of Scientific Informatics at Certara, explain how scientific intelligence can refine and increase the effectiveness of critical decision points in drug discovery. Strong scientific intelligence capabilities are essential building blocks for a scientific informatics strategy and will increase the effectiveness of… Read More

#Exclusive Content #News

#Biopharmaceutical #Drug development #Events #Webinar

Webinar: Addressing analytical challenges in biosimilar development 

The route to market for biosimilars places strong emphasis on characterisation tools for establishing comparability between biosimilar and innovator products.   Addressing analytical challenges in fast-forwarding biosimilar development processes requires Implementing sophisticated analytical instruments with advanced technologies. The ICH Q6B, cited by both EMA and FDA, highlights electrophoretic data as… Read More

#News

#Biopharmaceutical #Clinical trials #Drug delivery #Drug development

First patient dosed in izokibep trial for patients with active AS

Inmagene Biopharmaceuticals and Affibody have dosed the first patient in the global ASPIRE Phase II trial evaluating izokibep (IMG-020 or ABY-035) for the treatment of ankylosing spondylitis (AS).  “Dosing the first patient in the global Phase II AS trial is an important milestone for the izokibep programme,” said Dr. Jean-Louis Saillot, Inmagene’s Chief… Read More

#News

#Biopharmaceutical #Pharmaceuticals

UK’s ABPI releases ‘substantial overhaul’ to Code of Practice

The President of the UK’s Association of the British Pharmaceutical Industry (ABPI) has announced that its 2021 Code of Practice puts new emphasis on the ABPI’s principles. “We want everyone in pharmaceutical companies to live and breathe these from leadership teams and commercial leads to admin assistants and research scientists. Read More

#News

#Biopharmaceutical #Molecular Biology #Whitepaper

What makes a great BioELN?

In this latest DDW whitepaper, brought to you by PerkinElmer Informatics, John Conway, is Chief Visioneer Officer at 20/15 Visioneers, tackles defining “What Makes a Great BioELN” in this thoughtful and informative industry perspective. The whitepaper covers the six high-level workflows a great BioELN must include; what the team personas… Read More

#News

#Antibodies #Biopharmaceutical #Collaboration #Sitting Down With

Antibody engineering: the importance of collaboration and successful partnerships

The latest DDW Sponsored Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. Listen to hear Mathur discuss the company philosophy, how the pandemic has affected… Read More

#Podcasts

#Antibodies #Biopharmaceutical #Collaboration

Antibody engineering: the importance of collaboration – podcast

The latest DDW Sitting Down With podcast features Melina Mathur, Product Manager for Biopharma at Twist Bioscience. Mathur talks about Twist’s antibody expertise, drawing on the company’s experience and looking at the importance of collaboration. The company has created some successful partnerships and she explains what these look like, why… Read More

#Editor's Choice #News

#Biopharmaceutical #Covid-19 #Life sciences #Pharmaceutical research #Vaccines

ABPI chief stresses importance of research investment

The Chief Executive of the UK’s Association of the British Pharmaceutical Industry (ABPI), Richard Torbett, has stressed the importance of investment in research in response to the Queen’s Speech delivery. “The response to the pandemic has shown just how critical the UK’s pharmaceutical industry is to our country’s future and… Read More

#News #Trending News

#Awards #Biopharmaceutical

GW Pharmaceuticals awarded Queen’s Award for Enterprise in Innovation

GW Pharmaceuticals has received the Queen’s Award for Enterprise 2021 in the Innovation category, recognising the company’s work to harness cannabinoid science to create the world’s first regulatory approved, prescription cannabis-based medicines. Since its inception in 1998, GW worked on the development, manufacture and commercialisation of regulatory approved cannabis-based medicines. Read More

#News